Figure 2.

Evaluation of sestamibi uptake and proliferation index in patients affected by hyperparathyroidism. (A) Graph shows linear regression analysis between the percentage of Ki67 positive cells and lesion to nonlesion (L/N) ratio. (B) Graph displays linear regression analysis between the number of mitosis and L/N ratio. (C) Graph shows linear regression analysis between patients’ year and L/N ratio. (D) Graph displays linear regression analysis between patients’ year and the percentage of Ki67-positive cells. (E) Image shows [⁹⁹mTc]Sestamibi uptake in a 74-year-old woman with primary hyperparathyroidism. A parathyroid carcinoma (0.8 cm) was identified after the surgery by histological analysis. To evaluate the parathyroid sestamibi uptake, that of the thyroid has been subtracted. (F) Representative image of immunohistochemical reaction for ki67. Several positive Ki67 cancer cells are labeled by arrows. (G) Hematoxylin–eosin (H&E) staining shows several mitosis (arrows). (H) Image displays no [⁹⁹mTc]Sestamibi uptake in a 40-year-old woman with primary hyperparathyroidism. A parathyroid adenoma (0.4 cm) was identified after the surgery by histological analysis. (I) Representative image of immunohistochemical reaction for Ki67. Rare positive Ki67 cancer cells are labeled by arrows. (J) H&E staining shows rare mitosis (arrows). Scale bar represents 100 µm in all images.